Figure 1From: Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer Management of (a) the first occurrence of neutropenia using rescue G-CSF and (b) subsequent treatment cycles in patients who have received rescue G-CSF in cohort 2. Back to article page